| |
|
|
|
| |
M-RCBG CELEBRATES 25 YEARS |
OCTOBER 23 & 24 | 2007 |
|
| |
1982 - 2007 |
|
|
| |
|
|
|
| |
NEW DIRECTIONS IN |
REGULATORY POLICY |
|
| |
|
|
|
| |
|
|
|
| |
_____________________________________________ |
|
|
| |
Regulating Medicine
Mark McClellan
Former Administrator, Ctrs. for Medicare & Medicaid
Fellow, The Brookings Institution
 "For the first time we have the potential for a timely and reliable monitoring system for [drugs'] rare side effects that should never happen, or side effects that are suspected in actual use, but can’t be proven in a free market setting of clinical trials that can’t mimic all the real world conditions and patients’ circumstances that inevitably arise. With new steps, the public can have much more confidence that just because a drug gets to market, it won’t be many years before we get to more definitive evidence about drugs’ risk and benefits."
-Mark McClellan
Student Rapporteur Report of McClellan Forum |
The Role of Government in Markets
The Honorable Christopher Cox
Chairman, U.S. Securities & Exchange Commission
 "Even the economic rationale for our legislative and regulatory deference to markets is called into question when the major marketplace participants are not profit-maximizing individuals, but governments with national interests. A nation’s interests – and the interests of its government, to the extent they same – are certainly legitimate. But by definition, a nation’s interests extend beyond simply seeking return on investment through economic gains and the avoidance of economic loss."
- Christopher Cox
|
|
| |
_____________________________________________ |
_____________________________________________ |
|
| |
|
|
|
| |
PANELS |
|
|
| |
_____________________________________________ |
_____________________________________________ |
|
| |
PANEL I
Robert Stavins, Kennedy School of Government
Joseph Aldy, Resources for the Future
Scott Barrett, Johns Hopkinis University
Jeffrey Frankel, Kennedy School of Government
Student Rapporteur Report of Panel I
|
 "The fact that you can’t really keep a country in a treaty under an existing treaty law means that you have to find better ways to promote their participation and compliance."
-Joseph Aldy, Panel I
Resources for the Future
|
|
| |
_____________________________________________ |
_____________________________________________ |
|
| |
PANEL II
 “We could minimize the needs to regulate the markets if we could
ensure the fundamental rights of shareholders.”
- Abe Friedman, Panel II
Director of Proxy Voting Barclays Global Advisors
|
Robert Glauber, Kennedy School of Government
John Dugan, Office of the Comptroller General
Abe Friedman, Barclays Global Advisors
Tom Russo, Lehman Brothers
Student Rapporteur Report of Panel II
|
|
| |
_____________________________________________ |
_____________________________________________ |
|
| |
PANEL III
Joseph Newhouse, Kennedy School of Government
Alison Taunton-Rigby, RiboNovix
David Nexon, AdvaMed
Jack Schuler, Stericycle
Dr. Janet Woodcock, U.S. FDA
Student Rapporteur Report of Panel III |
Alison Taunton-Rigby
|
|
| |
_____________________________________________ |
_____________________________________________ |
|
| |
PANEL IV
|
Jorge Segrelles, Repsol-YPF Foundation
Elizabeth Moler, Exelon Corporation
Erich Muehlegger, Kennedy School of Government
Jim Sweeney, Stanford University
Student Rapportuer Report of Panel IV
|
|
| |
|
|
|
| |
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
